[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neuroendocrine-ne-tumors\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neuroendocrine-ne-tumors":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,46,82,106,129,155,180,205],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100643218","phase-2-aur103-calcium-in-advanced-neuroendocrine-tumours-bharat-3-study-100643218",false,"NCT07640737","AUR103 Calcium in Advanced Neuroendocrine Tumours (BHARAT-3 Study)","A Phase 2 Study Evaluating the Efficacy and Safety Agent AUR103 Calcium in Patients With Advanced, Well or Moderately Differentiated Neuroendocrine Tumours (BHARAT-3)","BHARAT-3","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Eastern Coorperative Oncology Group (ECOG) Performance status of 0 or 1.\n3. Pathologically confirmed, well or moderately differentiated (G1 or G2), advanced (unresectable or metastatic), neuroendocrine tumour.\n4. Patients should have progressed after at least one line of therapy.\n\n   Notes:\n   1. All previous treatments are allowed\n   2. There is no upper limit on the number of prior lines of therapy.\n   3. Patient should have received at least one FDA approved therapy for his\u002Fher disease (i.e., Patient should have received at least one of everolimus, sunitinib, cabozantinib or Lu177 dotatate for his\u002Fher specific NET, as per FDA approved package insert).\n   4. SSA (Somatostatin Analogues) alone is not considered a line of therapy for Inclusion criterion 4.\n5. Disease progression with last line of therapy.\n6. Measurable disease by RECISTv1.1.\n7. If the patient is receiving Somatostatin analouges (SSA), the patient should be on stable doses for at least 2 months.\n\n   \\[Note: Concomitant Somatostatin analouges (SSA) are allowed. No other therapies for NET are allowed along with study drug (e,g., everolimus, sunitinib, cabozantinib, peptide receptor radionuclide therapy (PRRT), chemotherapy etc.)\\].\n8. Acceptable bone marrow and organ function at screening as described below:\n\n   1. ANC ≥1000\u002F μL\n   2. Platelet count ≥ 80,000\u002FμL\n   3. Hemoglobin ≥ 9 g\u002FdL (Transfusion is allowed to achieve this Hb)\n9. Total Bilirubin ≤ 1.5 x ULN (Patients with known Gilbert's syndrome are allowed with a Total Bilirubin ≤ 2.5 x ULN).\n10. AST (SGOT) ≤ 3 x ULN (≤ 5 x ULN if known liver metastasis).\n11. ALT (SGPT) ≤ 3 x ULN (≤ 5 x ULN if known liver metastasis).\n12. Creatinine clearance (CrCl) ≥ 60 mL\u002Fmin (either measured or estimated by the Cockcroft-Gault formula).\n\n(Note: Cockcroft-Gault formula for estimated creatinine clearance \\[eCrCl\\]: eCrCl = \\[140- Age\\] × Weight \\[kg\\] × \\[0.85 if Female\\] \u002F \\[72 × serum creatinine (mg\u002FdL)\\]).\n\n\\-\n\nExclusion Criteria:\n\n1. Neuroendocrine carcinoma, such as small cell carcinoma.\n2. Grade 3 neuroendocrine tumours (NET) and\u002For Poorly differentiated NET.\n3. Patients with known MEN-1 (Multiple Endocrine Neoplasia-1) or MEN-2 (Multiple Endocrine Neoplasia-2) syndromes.\n4. Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral AUR103 calcium.\n5. Systemic anti-cancer therapy, such as small molecule TKIs, mTOR inhibitors, chemotherapy, biological therapy, or immunomodulatory drug therapy, received within the past 28 days or 5 half-lives, whichever is longer, from the Cycle 1 Day 1 of the study.\n\n   \\[Note: Concomitant use of SSA is allowed\\].\n6. Patients who have used PRRT as a previous line would require 6 weeks from the last dose, before Cycle 1 Day 1.\n7. Presence of an acute or chronic toxicity resulting from prior anticancer treatment, except for alopecia or nail changes, that has not resolved to Grade ≤ 1, as determined by NCI CTCAE v 5.0.\n8. Use of any investigational agent within 21 days or 5 half-lives (whichever is longer) prior to Cycle 1 Day 1.\n9. Known symptomatic or untreated or recently treated (≤ 6 months of screening) CNS metastases. Patients with previously treated (\\> 6 months of screening) brain metastasis and are now stable and asymptomatic, from CNS perspective, are allowed.\n10. Major surgery ≤ 28 days from Cycle 1 Day 1 (major surgery is defined as a procedure requiring general anesthesia).\n11. Hepatic intra-arterial embolization within the last 6 months. Cryoablation or radiofrequency ablation of hepatic metastases within 2 months of randomization.\n12. Presence of any additional malignancy within last 3 years, except basal-cell or squamous cell carcinoma of the skin or carcinoma-in situ of the uterine cervix.\n\n    \\[Note: Patients with other malignancies are eligible if they have remained disease free for at least 2 years prior to trial entry and in the opinion of the investigator deemed to have a low likelihood of recurrence\\].\n13. Active infection requring systemic therapy. \\[Note: Prophylactic use of antibiotics is allowed. Any infection detected during screening period which is resolved adequately according to investigator before the Cycle 1 Day 1, is allowed\\].\n14. Known to be human immunodeficiency virus (HIV) positive or have an acquired immunodeficiency syndrome-related illness.\n15. Known active or chronic hepatitis B (HBsAg +ve), hepatitis C infection (HCV antibody +ve).\n16. Expected to require any other form of antineoplastic therapy or targeted therapy while on study.\n17. Uncontrolled congestive heart failure (New York Heart Association \\[NYHA\\] Class 2-4), angina, myocardial infarction, cerebrovascular accident, coronary\u002Fperipheral artery bypass graft surgery, or transient ischemic attack, or pulmonary embolism within 3 months prior to Cycle 1 Day 1.\n18. Ongoing cardiac dysrhythmias requiring treatment of any grade or treatment of cardiac dysrhythmias in past 3 months, before Cycle 1 Day 1.\n19. Mean QTcF (Fridericia) interval \\>460 ms on ECG at screening or at Cycle 1 Day 1 pre-dose.\n20. Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or significant gastritis, active bleeding diatheses, presence of any major medical illness (e.g., renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, or psychiatric illness\u002Fsocial situations or clinically significant laboratory \u002F ECG abnormalities at screening, any or a combination of illnesses), which, in the opinion of the principal investigator (PI), may either put the patient at risk because of participation in the study, or influence the results or the patient's ability to participate in the study.\n21. Current swab-positive or suspected (under investigation) COVID-19 infection or fever and other signs or symptoms suggestive of COVID19 infection with recent contact of person(s) with confirmed COVID19 infection, at screening or Day 1 of Cycle 1.\n22. Positive pregnancy test for women of child-bearing potential (WOCBP) at the screening or enrolment visit, or lactating women.\n23. Women of child-bearing potential (WOCBP) who are neither surgically sterilized nor willing to use reliable contraceptive methods (hormonal contraceptive, IUD, or any double combination of male or female condom, spermicidal gel, diaphragm, sponge, cervical cap).\n\n    \\-","ALL","18 Years","99 Years",{"count":21,"type":22},30,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","A phase 2 Study Evaluating the Efficacy and Safety of Single Agent AUR103 Calcium in Patients with Advanced, Well or Moderately differentiated Neuroendocrine Tumours.\n\nThis is a Proof of Concept (PoC) Phase 2 study of AUR103 calcium in patients with advanced, well or moderately differentiated neuroendocrine tumours.\n\nThe main objective is to evaluate the efficacy of AUR103 calcium in patients with well or moderately differentiated neuroendocrine tumors.\n\nPatients with relapsed\u002Frefractory well or moderately differentiated neuroendocrine tumors.\n\nAUR103 calcium will be administered twice daily. Patients will receive AUR103 calcium until disease progression or intolerable toxicity.",[28,29],"Neuroendocrine (NE) Tumors","Advanced NET of GI Origin",[31,32],"NET Neuroendocrine Tumours","Neoplasms","NOT_YET_RECRUITING","2026-06-10",{"date":36,"type":37},"2026-06-11","ACTUAL",{"date":39,"type":22},"2026-06-30",{"date":41,"type":22},"2029-01-31",{"name":43,"class":44},"Aurigene Discovery Technologies Limited","INDUSTRY",5,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":81},"100614822","phase-2-ultralow-dose-pet-imaging-of-sstr2-radiotracer-uptake-100614822","NCT07284589","Ultralow Dose PET Imaging of SSTR2 Radiotracer Uptake","Evaluation of Ultralow Dose PET Imaging for Detecting SSTR2 Radiotracer Uptake","Inclusion Criteria:\n\n* Age ≥18 years.\n* Ability to provide informed consent and comply with study procedures.\n* For female participants: Must not be pregnant or breastfeeding; Negative pregnancy test required for women of childbearing potential.\n\nExclusion Criteria:\n\n* Participants who have exceeded NRC regulation for annual radiation exposure from prior research-related scans, including this study (50 millisievert \\[mSv\\] total).\n* More than four prior enrollments in this study.\n* Participants with severe claustrophobia, chronic pain, or musculoskeletal conditions that prevent completion of the PET scan\n* Medication \\& Prior Treatment Exclusions: SSTR targeted therapies\n* Pregnant or breastfeeding individuals (negative pregnancy test required)\n* Inability to provide informed consent\n* Any condition that, in the investigator's judgment, may compromise participant safety or study integrity.",true,"120 Years",{"count":56,"type":22},200,[25],"The goal of this clinical trial is to evaluate an investigational ultralow dose positron emission tomography (PET) imaging technique for neuroendocrine tumor detection and monitoring. The main question it aims to answer is:\n\nCan the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? Participants will be injected with a radioactive tracer that binds to a tumor specific protein called somatostatin receptor 2 (SSTR2) and be imaged on a new type of high sensitivity PET scanner for up to 3 hours",[60,61,28],"Healthy (Controls)","Healthy Volunteers",[63,64,65,66,67,68,69],"PET","PET\u002FCT","SSTR2","neuroendocrine","dotatate","low dose","nuclear imaging","RECRUITING","2026-04-07",{"date":73,"type":37},"2026-04-08",{"date":75,"type":37},"2025-12-11",{"date":77,"type":22},"2030-04-30",{"name":79,"class":80},"Akiva Mintz","OTHER",1,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":81},"100576570","resection-of-the-primary-tumor-vs-systemic-treatment-alone-for-patients-with-small-intestinal-neuroendocrine-tumors-and-unresectable-metastases-a-europe-wide-study-100576570","NCT06787014","Resection of the Primary Tumor vs. Systemic Treatment Alone for Patients With Small Intestinal Neuroendocrine Tumors and Unresectable Metastases: a Europe-wide Study","Resection of the Primary Tumor vs. Systemic Treatment Alone for Patients With Small Intestinal Neuroendocrine Tumors and Unresectable Metastases: a Retrospective, Europe-wide, Pooled Cohort Study (ENETS-SurgSmInt)","ENETSSurgSmInt","Inclusion Criteria:\n\n\\- All patients with siNET and non-curative metastatic disease between 01.01.2005 and 31.12.2021 will be included.\n\nExclusion Criteria:\n\n\\- All patients with siNET G3, resectable metastatic disease and\u002For non-resectable primary tumor at initial diagnosis will be excluded. Furthermore, symptomatic patients (small intestinal obstruction, bleeding) or when imaging suggests that obstruction will probably occur (bowel dilatation, mesenteric fibrosis) at initial diagnosis will be excluded. Patients with diarrhea, flushing, or abdominal pain will not be excluded.\n\nPatients with a documented rejection for a further use of their data for scientific purposes will also be excluded.",{"count":91,"type":22},3200,"OBSERVATIONAL","When possible, surgery to completely remove small intestinal neuroendocrine tumors (siNETs) is always recommended. However, in cases where the tumor has spread and cannot be cured completely, it is unclear whether a surgical removal of the primary tumor only is reasonable. In this situation, current guidelines from the European Neuroendocrine Tumor Society (ENETS) recommend surgery only for patients who have symptoms like intestinal blockage or bleeding, or are at risk of such complications. For patients without symptoms, it is still unclear whether removing the main tumor improves overall outcomes and prevents future problems.\n\nStudies evaluating this type of surgery on survival show conflicting results. These studies often do not separate patients with symptoms from those without, and they overlook other important factors like the amount of cancer in the liver and nearby tissues. Due to these uncertainties, the rarity of siNETs and many factors that can affect outcomes, like age, overall health, or other current treatments, conducting a high-quality study to answer this question is challenging. To address this, the present Europe-wide study is being planned.\n\nThis study aims to determine if resecting the main tumor improves the 10-year overall survival and reduces risks like intestinal blockages or blood flow issues compared to no surgery in patients without symptoms. The study will also assess other outcomes, such as how long patients stay free from disease progression, the risks of surgery, and prognostic factors for long-term survival. This international collaboration among neuroendocrine tumor referral centers will provide robust evidence to guide clinical practice and update treatment guidelines for siNETs.",[28,95,96],"Metastasis","Bowel Obstruction","2026-03-17",{"date":99,"type":37},"2026-03-18",{"date":101,"type":37},"2026-03-09",{"date":103,"type":22},"2028-12-31",{"name":105,"class":80},"Insel Gruppe AG, University Hospital Bern",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":114,"targetDuration":116,"studyType":92,"phases":4,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":128},"100629188","survival-without-persistent-limiting-toxicity-real-life-prospective-cohort-of-advanced-neuroendocrine-tumor-100629188","NCT07471425","Survival Without Persistent Limiting Toxicity: Real Life Prospective Cohort of Advanced Neuroendocrine Tumor","Survival Without Persistent Limiting Toxicity: a Real Life Prospective Cohort of Advanced Neuroendocrine Tumor Followed in the French ENDOCAN-RENATEN and GTE Networks","TOLERATE","Inclusion Criteria:\n\n* Unresectable local or metastatic NET naive of treatment tumor except somatostatin analogues or primary surgery.\n* Unresectable local or metastatic NET newly diagnosed\\\u003C6 months whatever the primary NET site\n* Well differentiated neuroendocrine tumor (WHO classifications) pathologically reviewed locally\n* No initial medical absolute contraindication to any of the authorized or recommended treatments (no AE\\>grade 1 according to NCI CTC v.5 criteria),\n* Patient who have full medical follow-up in an expert center of the French ENDOCAN network for the management of their advanced neuroendocrine tumor\n* Patient not opposed to data collection in the on GTE databasis\n* Patient not opposed to participate in the clinical study\n\nExclusion Criteria:\n\n* Patients with severe illness that contraindicates participation to any study\n* Age \\\u003C18 years old",{"count":115,"type":22},1100,"5 Years","Advanced neuroendocrine tumors (NETs) are rare cancers, characterized by prolonged survival (median\\>5 years). If five medical options are now approved and 4 others are only recommended, the best sequence is still unknown. No single study on long-term cumulative toxicity of consecutive treatment interventions has been published so far. Taking into account real-world context is required for sound decision- making that cannot be answered by randomized trials.\n\nProject objectives and brief description of the methods, which will be used to achieve them: Study team will construct a longitudinal prospective cohort of consecutive non resectable or metastatic NET patients using the GTE-RENATEN network to evaluate the real world cumulative and limiting toxicities. They will expect, as primary endpoint, a difference in survival without limiting (\\>grade 1 adverse event according to nci.ctc V5) persistent (\\>6 months) toxicity between therapeutics classes or therapeutics sequences in the real life conditions all along the treatments lines, since metastasis diagnosis. All NET primary patients will be enrolled.\n\nPatients will be followed until the primary endpoint is reached, death or until 5 years.\n\nBased on our pilot study, we plan to enroll 1100 patients to detect 150 events and adjust for 15 cofounders and 10% of lost to follow-up. Cox model adapted to time-related dependency will be used to analyze the data and machine learning will be utilized to take into account the number of confounding factors, interactions and nonlinear relationship. The best model of prediction will be validated in a subgroup of the cohort population.\n\nExpected results: Study team will create a tool to help therapeutic decision in order to identify in a given patient the best therapeutic class or sequence with the lowest risk of persistent limiting toxicity.",[28],"2026-03-12",{"date":121,"type":37},"2026-03-13",{"date":123,"type":22},"2026-06",{"date":125,"type":22},"2034-06",{"name":127,"class":80},"Gustave Roussy, Cancer Campus, Grand Paris",14,{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":138,"conditions":139,"keywords":142,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":81},"100612840","evaluation-of-tolerance-and-quality-of-life-in-patients-with-neuroendocrine-tumors-treated-with-oral-anti-tumor-drugs-within-a-therapeutic-education-program-100612840","NCT07258810","Evaluation of Tolerance and Quality of Life in Patients With Neuroendocrine Tumors Treated With Oral Anti-Tumor Drugs Within a Therapeutic Education Program","ETP-NET","Inclusion Criteria:\n\n* Adult patient (\\>18 years) at the time of the study\n* Patient diagnosed with a neuroendocrine tumor (NET) with an indication for treatment with oral anti-tumor agents (everolimus, sunitinib, cabozantinib, temozolomide +\u002F- capecitabine, others including lenvatinib)\n* Collection of the patient's non-opposition to participate in the study\n\nExclusion Criteria:\n\n* Minors\n* Pregnant, parturient, or breastfeeding women\n* Persons deprived of liberty by judicial or administrative decision\n* Adults under legal protection measures (guardianship, conservatorship)\n* Refusal to participate in the study",{"count":137,"type":22},100,"In recent years, the arrival of targeted oral therapies has greatly changed cancer treatment. These therapies help patients stay independent by reducing the number of hospital visits, since the treatment is given at home. However, this way of giving treatment brings specific challenges, especially in managing side effects and making sure patients follow their treatment properly.\n\nBecause of this, many patient education programs have been created to help patients learn how to manage their treatment on their own. Although only a few studies have formally looked at how useful these programs are, the available information suggests that they help patients handle side effects better and follow their treatment more closely.\n\nNeuroendocrine tumors are a diverse group of tumors that are becoming more common. More patients with these tumors are now treated with targeted oral therapies such as everolimus, sunitinib, cabozantinib, or chemotherapy with temozolomide and capecitabine.\n\nThese treatments are often given together with a patient education program. However, so far, no study has specifically looked at how helpful these education programs are for this group of patients.",[28,140,141],"Oral Anti-Tumor Drugs","Therapeutic Education Program",[143,140,141,144,145],"Neuroendocrine tumor","Tolerance","Quality of Life","2025-11-21",{"date":148,"type":37},"2025-12-02",{"date":150,"type":22},"2025-12-01",{"date":152,"type":22},"2027-02-01",{"name":154,"class":80},"Hospices Civils de Lyon",{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":165,"conditions":166,"keywords":168,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":81},"100602322","study-of-acquired-resistance-to-alkylator-chemotherapy-in-endocrine-neoplasms-100602322","NCT07121998","Study of Acquired Resistance to Alkylator Chemotherapy in Endocrine Neoplasms","Longitudinal Biomarker Study in Endocrine Neoplasms to Study Acquired Resistance to Alkylator Chemotherapy","PROGRESS-TMZ","Inclusion Criteria:\n\n* Informed consent\n* Age ≥18 years\n* Histopathology confirmed endocrine neoplasm\n* Treatment with alkylating chemotherapy: Arm A; about to start alkylating chemotherapy, or Arm B; at disease progression or recurrence with previous alkylating chemotherapy treatment.\n\nExclusion Criteria:\n\n* If planned tissue biopsy: risk factors for biopsy-related complications accordingly to local investigator, including coagulation disorder\n* Long term treatment with anticoagulant that cannot be temporarily paused without unacceptable risk\n* Pregnancy",{"count":164,"type":22},94,"It has been showed that alkylating chemotherapy, particularly the widely used agent temozolomide, may cause high tumor mutational burden (TMB) in certain tumors by causing inactivating mutations in the DNA mismatch repair (MMR) system. This can cause therapy resistance and tumor progression but may also predict response for immunotherapy. Hypermutation is very uncommon in neuroendocrine tumors. However, small studies indicate that around 30% of pancreatic tumors develop high TMB after alkylating chemotherapy. The aim of this study is therefore to study the occurrence and frequency of DNA hypermutation after alkylating chemotherapy in endocrine neoplasms and to investigate non-invasive methods that may capture the development of hypermutation (imaging, ctDNA etc.).\n\nThis is a prospective multicenter study. 94 patients from Swedish endocrine cancer centers in Uppsala, Stockholm, Göteborg and Lund will be included and divided into two groups. Group A will include patients that are about to start treatment with alkylating chemotherapy. Blood samples for liquid biopsy will be collected at baseline and at follow-up and if the tumor progresses, tissue biopsy will be obtained from two different lesions and analyzed with GMS560. Group B will include patients experiencing tumor progression after having received alkylating chemotherapy at any point in their disease course before. At inclusion, both liquid and tissue biopsy will be obtained and analyzed as described above.",[28,167],"Endocrine Cancer",[169,170],"Alkylating chemotherapy","Treatment resistance","2025-08-10",{"date":173,"type":37},"2025-08-14",{"date":175,"type":37},"2025-03-01",{"date":177,"type":22},"2030-03-01",{"name":179,"class":80},"Uppsala University",{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":190,"conditions":191,"keywords":193,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":203,"locationsCount":81},"100591517","life-following-excision-of-neuroendocrine-tumors-100591517","NCT06981455","Life Following Excision of Neuroendocrine Tumors","LIFE-NETs (Life Following Excision of Neuroendocrine Tumors): a Multi-institutional Prospective Observational Cohort Study of Quality of Life After Surgery for Neuroendocrine Tumors","LIFENETS","Inclusion Criteria:\n\n* Age \\>18 years old\n* Diagnosis of well-differentiated grade 1 to 3 NETs via histopathology (biopsy) or imaging (measurable tumor on CT or MRI with avidity on SSTR-PET scan).\n* Consents to surgery for resection of localized, loco-regional, or metastatic gastro-enteric (midgut) and pancreatic neuroendocrine tumor (GEP-NET).\n\nExclusion Criteria:\n\n* Pre-operative diagnosis of neuroendocrine carcinoma on histopathology (biopsy) or imaging (measurable tumor on CT or MRI with avidity on FDG-PET scan and no avidity on SSTR-PET scan).\n* Declines surgery.\n* Unable to respond to study questionnaires (not proficient in local language).",{"count":189,"type":22},246,"Neuroendocrine tumors (NETs), often seen as \"chronic cancer\" present a survival paradox with relatively prolonged patient survival despite active disease. Treatment strategies emphasize management over cure, integrating tumor control with quality of life (QOL) considerations. Surgery is a cornerstone of NET management but demands a careful balance between its potential benefits and the morbidity risks. Current literature on post-surgical QOL is limited and non-generalizable, underscoring the need for comprehensive, multi-institutional data to inform surgical decisions.\n\nWe will study QOL after surgery for NETs in a prospective multi-institutional international cohort study. Specifically, we aim to 1) describe the post-operative QOL of patients with NETs and 2) identify factors associated with QOL measures after surgery for NETs. This project will be led in partnership by the Susan Leslie Clinic for NETs at Sunnybrook Health Sciences Centre in Toronto, Canada, and the IRCCS San Raffaele ENETS Centre of Excellent in Milan, Italy, and enrol adults undergoing surgery for resection of gastro-entero-pancreatic NETs across 12 North-American and European high-volume NETs surgery centres over a 18-month period. Measures of QOL using the SF-12 Survey, the EORTC-QLQ C30 and GEPNET21 tool, and clinical symptoms assessment, will be captured prior to surgery and at 6, 12, 24, and 36 months after surgery. Mixed linear regression models with random intercepts to account for longitudinal data correlation and individual variability will be used to analyze the QOL measures over time. Patient and service users engagement (PSUE) will be integrated throughout the study continuum.\n\nThis project will fill the knowledge gap in QOL after surgery for NETs, with a view to support better-informed surgical decisions and patient-centred care. The prospective, multi-institutional, and international design promises a comprehensive understanding of the impact of surgery on patient's lives, potentially shaping management pathways globally.",[28,192],"Neuroendocrine Tumor GEP Grade 1-3",[194,195,196,66],"surgery","quality of life","carcinoid","2025-05-13",{"date":199,"type":37},"2025-05-20",{"date":201,"type":37},"2025-04-28",{"date":103,"type":22},{"name":204,"class":80},"Sunnybrook Health Sciences Centre",{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":212,"targetDuration":4,"studyType":23,"phases":214,"briefSummary":216,"conditions":217,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":81},"100575541","use-of-68ga-dotatoc-petct-enterography-for-detection-of-the-primary-lesion-in-neuroendocrine-tumors-of-the-small-bowel-100575541","NCT06773624","Use of 68Ga-DOTATOC PET\u002FCT-enterography for Detection of the Primary Lesion in Neuroendocrine Tumors of the Small Bowel","Evaluation of 68Ga-DOTATOC PET\u002FCT-enterography for the Detection of the Primary Lesion in Neuroendocrine Tumors of the Small Bowel","Inclusion Criteria:\n\n* patients with small bowel neuroendocrine tumours\n* tumors with any grade (from 1 to 3) and any Ki 67 percentage\n* patients eligible for surgical resection\n\nExclusion Criteria:\n\n* patients with synchronous other oncological disease\n* patients with Inflammatory bowel disease\n* patients Not eligible for surgery",{"count":213,"type":22},18,[215],"NA","The neuroendocrine neoplasms of the small intestine (Si-NENs) is a relatively rare malignancy. Surgical resection is the only curative treatment for the early-stage. It remains controversial its application for advanced metastatic gastroenteropancreatic neuroendocrine tumours (GEP-NETs).\n\nThe identification of metastatic disease and tumor grade are the most important prognostic factors in advanced GEPNETs. Therefore, precise staging and evaluation of disease burden with a reliable imaging method is crucial for determining the correct stage of the disease and consequently the correct treatment.\n\nA unique feature of NeuroEndocrinal Tumors (NETs) is the expression of somatostatin receptors (SSTR) which can be targeted with radiolabeled peptides for imaging.\n\nThe Positron Emission Tomography-Computed Tomography (PET\u002FCT) technique using somatostatin analogs labeled with the positron emitting isotope, 68Ga (68Ga-DOTA peptides), has been shown to offer advantages over conventional imaging modalities as well as additional important quantitative and qualitative diagnostic information.\n\nThe aim of this study is to calculate the sensitivity (SE), the specificity (SP), the positive and negative predictive values (PPV and NPV) and the overall accuracy of 68Ga-DOTATOC PET\u002FCT-enterography in detecting in primary lesion and multifocality of siNETs.",[218,28],"Small Bowel Neoplasia","2025-01-09",{"date":221,"type":37},"2025-01-14",{"date":223,"type":37},"2021-04-23",{"date":225,"type":22},"2026-12",{"name":227,"class":80},"European Institute of Oncology"]